| abstract |
An improved method for determining biomarker assays and / or drug targets for cancer diagnosis, prognosis, treatment and therapy monitoring. ASPN in human serum, plasma or blood or blood itself; VTN; AOC3; LOX; PGCP; PSAP; THBS1; CFH; CLU; KIT; TFRC; LGALS3BP; GOLPH2; HYOOU1; CTSD; OLFM4; AKAP13; CP; CPE; CPM; ICAM1; MSMB: TM9SF3; combined measurement of the concentration of at least 2, preferably at least 3 proteins and / or protein fragments selected from the group obtained from GALNTL4 was used A method for the diagnosis and / or treatment and / or monitoring of localized prostate cancer, in particular for differentiation from benign prostatic hyperplasia, said measurement being used for detection of these proteins / fragments thereof, tandem mass Related to analysis technology. [Selection figure] None |